Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
LONDON, 08 November 2021: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Autolus Therapeutics plc (Nasdaq: AUTL) (Autolus), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has entered into a strategic collaboration and financing agreement with Blackstone (NYSE: BX) under which funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of obe-cel in B-cell malignancies.
